Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis

Circulation

Volumn 109, Issue 12, 2004, Pages 1536-1542

  Candido, Riccardo ^a   Allen, Terri J ^a   Lassila, Markus ^a   Cao, Zemin ^a   Thallas, Vicki ^a   Cooper, Mark E ^a   Jandeleit Dahm, Karin A ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Angiotensin; Atherosclerosis; Diabetes mellitus; Vessels

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; CALCIUM ANTAGONIST; COLLAGEN; IRBESARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR B; STREPTOZOCIN; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; GENE OVEREXPRESSION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTIC DISEASES; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; BIPHENYL COMPOUNDS; CALCIUM CHANNEL BLOCKERS; CELL DIVISION; CHEMOKINE CCL2; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; STREPTOZOCIN; TETRAZOLES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 1842538570     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000124061.78478.94     Document Type: Article

References (30)

1. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937-942.
2. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294-2303.
3. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4:1025-1031.
4. Candido R, Jandeleit-Dahm KA, Cao Z, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation. 2002;106:246-253.
5. Willis AL, Nagel B, Churchill V, et al. Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Arteriosclerosis. 1985;5:250-255.
6. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest. 1981;68:1366-1369.
7. Kramsch DM. Limits of lipid-lowering therapy: the potential benefits of amlodipine as an antiatherosclerotic agent. Int J Cardiol. 1997;62(suppl 2):S119-S124.
8. Dol F, Martin G, Staels B, et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2001;38:395-405.
9. Keidar S, Attias J, Smith J, et al. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236:622-625.
10. Cristofori P, Lanzoni A, Quartaroli M, et al. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens. 2000;18:1429-1436.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
12. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355-1374.
13. Cao Z, Dean R, Wu L, et al. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension. 1999;34:408-414.
14. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation. 2001;103:448-454.
15. Kranzhofer R, Schmidt J, Pfeiffer CA, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:1623-1629.
16. Chen XL, Tummala PE, Olbrych MT, et al. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res. 1998;83:952-959.
17. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586-1593.
18. Makaritsis KP, Gavras H, Du Y, et al. Alpha1-Adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice. Hypertension. 1998;32:1044-1048.
19. Caligiuri G, Nicoletti A, Zhou X, et al. Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis. 1999;145:301-308.
20. Hodgin JB, Maeda N. Minireview: estrogen and mouse models of atherosclerosis. Endocrinology. 2002;143:4495-4501.
21. Paoletti R, Corsini A, Soma MR, et al. Calcium, calcium antagonists and experimental atherosclerosis. Blood Press Suppl. 1996;4:12-15.
22. Motro M, Shemesh J, Grossman E. Coronary benefits of calcium antagonist therapy for patients with hypertension. Curr Opin Cardiol. 2001;16:349-355.
23. Sima A, Stancu C, Constantinescu E, et al. The hyperlipemic hamster: a model for testing the anti-atherogenic effect of amlodipine. J Cell Mol Med. 2001;5:153-162.
24. Chen HJ, Li DY, Saldeen T, et al. Attenuation of tissue P-selectin and MCP-1 expression and intimal proliferation by AT(1) receptor blockade in hyperlipidemic rabbits. Biochem Biophys Res Commun. 2001;282:474-479.
25. Kislinger T, Tanji N, Wendt T, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2001;21:905-910.
26. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
27. Dansky HM, Barlow CB, Lominska C, et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol. 2001;21:1662-1667.
28. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
29. Pitt B, Byington RP, Furberg CD, et al, for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
30. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422-2427.